What is your strategy for assessment of mutations from a liquid biopsy in metastatic breast cancer that has progressed on multiple therapies?
Many times we encounter patients who do not have a tissue sample readily available or in whom obtaining such a sample would be hard. On a more molecular level, does the yield vary by use of PBMC vs ctDNA? In the absence of tumor tissue, how can we differentiate between somatic and germ-line mutations?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Texas MD Anderson Cancer Center
Answered on
The use of liquid biopsies in patients with metastatic breast cancer who have progressed on multiple therapies is primarily useful for patients eligible and interested in clinical trials in order to prioritize or qualify patients for targeted therapies. Concordance with results from tissue based tes...
Join for free or sign in to see the full answer